Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
Saved in:
| Title: | Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. |
|---|---|
| Authors: | Bonnefoi H; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France. Electronic address: h.bonnefoi@bordeaux.unicancer.fr., Lerebours F; Department of Medical Oncology, Institut Curie, St Cloud, France., Pulido M; Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux, France., Arnedos M; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Bordeaux, France., Tredan O; Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France., Dalenc F; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Université de Toulouse, Toulouse, France., Guiu S; Department of Medical Oncology, Institut du Cancer Montpellier - Val d'Aurelle Montpellier, France., Teixeira L; Department of Senologie, Hôpital Saint Louis, INSERM U976, Université Paris Cité, Paris, France., Mollon D; Department of Medical Oncology, Centre Hospitalier de Cornouaille, Quimper, France., Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France., Verret B; Department of Medical Oncology, Gustave Roussy, Villejuif, France., Dawood H; Department of Medical Oncology, Centre Hospitalier Régional, Orléans, France., Deiana L; Department of Medical Oncology, Centre Hospitalier Universitaire, Brest, France., Mouret Reynier MA; Department of Medical Oncology Centre Jean Perrin, Clermont Ferrand, France., Augereau P; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France., Canon JL; Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium., Huchet N; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France., Guyonneau C; R&D Department, UNICANCER, Paris, France., Lemonnier J; R&D Department, UNICANCER, Paris, France., MacGrogan G; Department of Pathology, Institut Bergonié, Bordeaux, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix Marseille Univ, Marseille, France., Darbo E; INSERM U1312, Université de Bordeaux, Bordeaux, France., Iggo R; INSERM U1312, Department of Medical and Biological Sciences, Université de Bordeaux, Bordeaux, France. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2025 Mar; Vol. 26 (3), pp. 355-366. Date of Electronic Publication: 2025 Feb 17. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39978376 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bonnefoi+H%22">Bonnefoi H</searchLink>; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France. Electronic address: h.bonnefoi@bordeaux.unicancer.fr.<br /><searchLink fieldCode="AU" term="%22Lerebours+F%22">Lerebours F</searchLink>; Department of Medical Oncology, Institut Curie, St Cloud, France.<br /><searchLink fieldCode="AU" term="%22Pulido+M%22">Pulido M</searchLink>; Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Arnedos+M%22">Arnedos M</searchLink>; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Tredan+O%22">Tredan O</searchLink>; Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France.<br /><searchLink fieldCode="AU" term="%22Dalenc+F%22">Dalenc F</searchLink>; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Université de Toulouse, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Guiu+S%22">Guiu S</searchLink>; Department of Medical Oncology, Institut du Cancer Montpellier - Val d'Aurelle Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Teixeira+L%22">Teixeira L</searchLink>; Department of Senologie, Hôpital Saint Louis, INSERM U976, Université Paris Cité, Paris, France.<br /><searchLink fieldCode="AU" term="%22Mollon+D%22">Mollon D</searchLink>; Department of Medical Oncology, Centre Hospitalier de Cornouaille, Quimper, France.<br /><searchLink fieldCode="AU" term="%22Levy+C%22">Levy C</searchLink>; Department of Medical Oncology, Centre François Baclesse, Caen, France.<br /><searchLink fieldCode="AU" term="%22Verret+B%22">Verret B</searchLink>; Department of Medical Oncology, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Dawood+H%22">Dawood H</searchLink>; Department of Medical Oncology, Centre Hospitalier Régional, Orléans, France.<br /><searchLink fieldCode="AU" term="%22Deiana+L%22">Deiana L</searchLink>; Department of Medical Oncology, Centre Hospitalier Universitaire, Brest, France.<br /><searchLink fieldCode="AU" term="%22Mouret+Reynier+MA%22">Mouret Reynier MA</searchLink>; Department of Medical Oncology Centre Jean Perrin, Clermont Ferrand, France.<br /><searchLink fieldCode="AU" term="%22Augereau+P%22">Augereau P</searchLink>; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.<br /><searchLink fieldCode="AU" term="%22Canon+JL%22">Canon JL</searchLink>; Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium.<br /><searchLink fieldCode="AU" term="%22Huchet+N%22">Huchet N</searchLink>; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Guyonneau+C%22">Guyonneau C</searchLink>; R&D Department, UNICANCER, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lemonnier+J%22">Lemonnier J</searchLink>; R&D Department, UNICANCER, Paris, France.<br /><searchLink fieldCode="AU" term="%22MacGrogan+G%22">MacGrogan G</searchLink>; Department of Pathology, Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Gonçalves+A%22">Gonçalves A</searchLink>; Department of Medical Oncology, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix Marseille Univ, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Darbo+E%22">Darbo E</searchLink>; INSERM U1312, Université de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Iggo+R%22">Iggo R</searchLink>; INSERM U1312, Department of Medical and Biological Sciences, Université de Bordeaux, Bordeaux, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Mar; Vol. 26 (3), pp. 355-366. <i>Date of Electronic Publication: </i>2025 Feb 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39978376 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(24)00737-X Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 355 Titles: – TitleFull: Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bonnefoi H – PersonEntity: Name: NameFull: Lerebours F – PersonEntity: Name: NameFull: Pulido M – PersonEntity: Name: NameFull: Arnedos M – PersonEntity: Name: NameFull: Tredan O – PersonEntity: Name: NameFull: Dalenc F – PersonEntity: Name: NameFull: Guiu S – PersonEntity: Name: NameFull: Teixeira L – PersonEntity: Name: NameFull: Mollon D – PersonEntity: Name: NameFull: Levy C – PersonEntity: Name: NameFull: Verret B – PersonEntity: Name: NameFull: Dawood H – PersonEntity: Name: NameFull: Deiana L – PersonEntity: Name: NameFull: Mouret Reynier MA – PersonEntity: Name: NameFull: Augereau P – PersonEntity: Name: NameFull: Canon JL – PersonEntity: Name: NameFull: Huchet N – PersonEntity: Name: NameFull: Guyonneau C – PersonEntity: Name: NameFull: Lemonnier J – PersonEntity: Name: NameFull: MacGrogan G – PersonEntity: Name: NameFull: Gonçalves A – PersonEntity: Name: NameFull: Darbo E – PersonEntity: Name: NameFull: Iggo R IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2025 Mar Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 26 – Type: issue Value: 3 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |
